drug · small molecule
infigratinib phosphate
Marketedupdated 3mo agoby QED Therapeutics Inc🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for cholangiocarcinoma and 1 investigational indication.
targets
Fibroblast growth factor receptor
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 28, 2028
~1.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Dec 11, 2034formulationUS 10278969
- Dec 11, 2034formulationUS 10278969
- Dec 11, 2034formulationUS 11160804
- Dec 11, 2034formulationUS 11160804
- Aug 25, 2029compositionUS 85520023.0y
- Aug 25, 2029compositionUS 85520023.0y
- Aug 6, 2028compositionUS 90678962.0y
- Aug 6, 2028compositionUS 90678962.0y
FDA exclusivities (4)
- May 28, 2028ODE-353Orphan Drug (7y)1.8y
- May 28, 2028ODE-353Orphan Drug (7y)1.8y
- May 28, 2026NCENew Chemical Entity (5y)
- May 28, 2026NCENew Chemical Entity (5y)
News(1)
- Biotechs bring big launches and pharma rivalries into Q2 earnings periodWith the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.biospace · 13d ago
Data sources
last refreshed 44m ago
Found something off?
comments(0)
5-min edit window · permanent after that